Sunday, June 21, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 449 of 1,261
  1. US 10532986

    Cyclic compound acting as PDE4 inhibitor

    Medshine Discovery Inc. · Granted Jan 14, 2020 · Expires Jan 9, 2040

    granted
  2. US 10532109

    Peptide-DNA chimeras for treatment of HER overexpressing cancers

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Jan 14, 2020 · Expires Jan 9, 2040

    granted
  3. US 10532106

    Bicyclic peptide ligands specific for MT1-MMP

    BicycleRD Limited · Granted Jan 14, 2020 · Expires Jan 9, 2040

    granted
  4. US 10532079

    Extracts and beverages containing 2,5-piperazinedione, 3,6-bis(phenylmethyl)-, (3S,6S)-

    SUNTORY BEVERAGE & FOOD ASIA PTE. LTD. · Granted Jan 14, 2020 · Expires Jan 9, 2040

    granted
  5. US 10532059

    Steroid hormone pharmaceutical composition

    Compass Therapeutics LLC · Granted Jan 14, 2020 · Expires Jan 9, 2040

    granted
  6. US 10533227

    Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer

    The Board of Regents of the University of Texas System · Granted Jan 14, 2020 · Expires Jan 9, 2040

    granted
  7. US 10532056

    Therapeutic compositions, combinations, and methods of use

    VERASTEM, INC. · Granted Jan 14, 2020 · Expires Jan 9, 2040

    granted
  8. US 10532040

    Methods of treating cancer with herbacetin

    Regents of the University of Minnesota · Granted Jan 14, 2020 · Expires Jan 9, 2040

    granted
  9. CA 3105778

    POLYTHERAPIE AVEC DES ANTAGONISTES DU CGRP ET DES DERIVES DE CLOSTRIDIUM

    ALLERGAN PHARMACEUTICALS INT LTD [IE] · Granted Jan 9, 2020 · Expires Jan 4, 2040

    granted
  10. US 10525052

    Abuse-deterrent drug formulations

    Collegium Pharmaceutical, Inc. · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  11. US 10526403

    Anti-activin A antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  12. US 10526297

    Benzylideneguanidine derivatives and therapeutic use for the treatment of protein misfolding diseases

    United Kingdom Research and Innovation · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  13. US 10526346

    Histone deacetylase inhibitors

    BIOMARIN PHARMACEUTICAL INC. · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  14. US 10526400

    Humanized pertussis antibodies and used thereof

    The Board of Regents of the University of Texas System · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  15. US 10526414

    Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastases

    VACCINEX, INC. · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  16. US 10525106

    Angiopoietin-based interventions for treating cerebral malaria

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  17. US 10526576

    Compositions and methods for differentiating stem cells into cell populations comprising beta-like cells

    REGENERATIVE MEDICAL SOLUTIONS, INC. · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  18. US 10525046

    Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

    ACADIA Pharmaceuticals Inc. · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  19. US 10526373

    Peptide showing melanin generation-promoting activity and use thereof

    CAREGEN CO., LTD. · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  20. US 10526397

    Non-immunogenic single domain antibodies

    Inhibrx, Inc. · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  21. US 10526370

    Pentapeptide associated with integrin receptor alpha vbeta3

    CHINA PHARMACEUTICAL UNIVERSITY · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  22. US 10526359

    Thiosaccharide mucolytic agents

    The Regents of the University of California · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  23. US 10526344

    Amino acid acylation reagents and methods of using the same

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted
  24. US 10526330

    JAK kinase inhibitor compounds for treatment of respiratory disease

    Theravance Biopharma R&D IP, LLC · Granted Jan 7, 2020 · Expires Jan 2, 2040

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.